Chemical formula: C₂₃H₂₇FN₄O₂ Molecular mass: 410.485 g/mol PubChem compound: 5073
Risperidone is indicated for:
Population group: only elderly (65 years old or older)
Risperidone is indicated for the treatment of schizophrenia.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only elderly (65 years old or older)
Risperidone is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)
Risperidone is indicated for the short-term symptomatic treatment (up to 6 weeks) of persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation diagnosed according to DSM-IV criteria, in whom the severity of aggressive or other disruptive behaviours require pharmacologic treatment. Pharmacological treatment should be an integral part of a more comprehensive treatment programme, including psychosocial and educational intervention. It is recommended that risperidone be prescribed by a specialist in child neurology and child and adolescent psychiatry or physicians well familiar with the treatment of conduct disorder of children and adolescents.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 - 65 years old)
Risperidone is indicated for the treatment of schizophrenia.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 - 65 years old)
Risperidone is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorders.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 - 65 years old)
Risperidone is indicated for the short-term treatment (up to 6 weeks) of persistent aggression in patients with moderate to severe Alzheimer’s dementia unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
